Please enable Javascript
Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Advertisement
Dr. Luminari Remarks on EU Approval of Odronextamab for DLBCL, Follicular Lymphoma
Stefano Luminari, MD
Aggressive B-Cell Lymphoma
|
October 3, 2024
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
View More
Tisagenlecleucel Remains Promising for Follicular Lymphoma in Extended Trial Follow-Up
Andrew Moreno
Follicular Lymphoma
|
October 4, 2024
Encouraging efficacy and safety seen over 17 months in a phase II trial continued into the trial's 29-month follow-up period.
Read More
European Commission Approves Odronextamab for Follicular Lymphoma, DLBCL
Melissa Badamo
Follicular Lymphoma
|
August 26, 2024
The approval is based on results from the phase I ELM-1 and phase II ELM-2 trials.
Read More
EC Grants Conditional Approval to Epcoritamab for Relapsed or Refractory Follicular Lymphoma
Andrew Moreno
Follicular Lymphoma
|
August 20, 2024
The conditional marketing authorization was given for use as monotherapy in adults after two or more lines of prior therapy.
Read More
Tisagenlecleucel Effective, Safe in Relapsed or Refractory Follicular Lymphoma
Andrew Moreno
Transplantation & Cellular Therapy
|
July 18, 2024
A phase II trial found antitumor effect across patient subgroups and independently of risk factors for disease progression.
Read More
Liso-Cel Shows Promise for Second-Line, Later Management of Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
October 4, 2024
Treatment with liso-cel was effective and safe in patients with relapsed or refractory follicular lymphoma in TRANSCEND FL.
Read More
Advertisement
ELARA Trial Update: Tisa-Cel Continues to Show Efficacy, Safety in Follicular Lymphoma
Melissa Badamo
Follicular Lymphoma
|
June 3, 2024
The median progression-free survival, duration of response, and overall survival were not reached.
Read More
Minimized MRD Positivity in Follicular Lymphoma Linked to Long-term Disease Control
Andrew Moreno
Follicular Lymphoma
|
June 3, 2024
MRD is closely associated with disease control success during and after induction therapy in FL, trial analysis finds.
Read More
Liso-Cel Receives Accelerated Approval for Relapsed or Refractory Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
August 23, 2024
The US FDA has granted accelerated approval for liso-cel in adult patients with relapsed or refractory follicular lymphoma.
Read More
Study Identifies Features that Predict Follicular Lymphoma Early Relapse
Patrick Daly
Follicular Lymphoma
|
April 9, 2024
Tumor cells in high-risk follicular lymphoma had enhanced B-cell receptor signaling and distinct follicular growth patterns.
Read More
FDA Declines BLA for Odronextamab for Non-Hodgkin Lymphoma
Melissa Badamo
Aggressive B-Cell Lymphoma
|
May 21, 2024
The approval was declined due to the enrollment status of the confirmatory trials.
Read More
FDA Approves Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
March 7, 2024
Common adverse reactions to zanubrutinib observed across studies included decreased neutrophil and platelet counts.
Read More
External Comparator Analysis Supports Long-term Value of Axi-Cel in Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
March 7, 2024
Axi-cel yielded improved long-term outcomes versus conventional treatments in extended follow-up of the ZUMA-5 trial.
Read More
Liso-Cel ‘Favorable’ Safety Profile in Second-line Follicular Lymphoma
Melissa Badamo
Follicular Lymphoma
|
February 16, 2024
At a median follow-up of 18.1 months, the ORR and CR rates were both 95.7% following liso-cel treatment.
Read More
Dr. Coombs Spotlights Recent CHIP Updates
Chadi Nabhan, MD, MBA, FACP
The HemOnc Pulse
|
February 15, 2024
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Listen Now
Expanded Indications for Liso-Cel Under Review in US, Japan
Patrick Daly
Mantle Cell Lymphoma
|
April 2, 2024
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Read More
FDA Requests Boxed Warning Label on CAR-T Therapies Used to Treat Blood Cancers
Leah Sherwood
Myeloma
|
February 2, 2024
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
Read More
Epcoritamab Produces Promising Responses in Patients With Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
February 20, 2024
Epcoritamab yielded deep responses with promising response rates in high-risk relapsed or refractory follicular lymphoma.
Read More
Dual Treatment Shows Promising Efficacy in Untreated Follicular Lymphoma
Melissa Badamo
Indolent B-Cell Lymphoma
|
February 2, 2024
The trial studied a fixed-duration regimen of mosunetuzumab plus lenalidomide in follicular lymphoma.
Read More
Phase II Study: Mosunetuzumab Shows ‘Highly Encouraging Efficacy’ in Follicular Lymphoma
Melissa Badamo
Indolent B-Cell Lymphoma
|
February 14, 2024
Among 26 response-evaluable patients, the best overall response rate was 96% and the complete response rate was 81%.
Read More
Load More
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MD
Executive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer